The official opening of the second office of the biopharmaceutical company AstraZeneca in Poland is planned for the beginning of July. The investment was located in the vicinity of the AGH University of Science and Technology, in the building belonging to this university. As part of the company’s development, close cooperation with Sano – Centre for Computational Personalised Medicine – International Research Foundation is planned.
Currently, AstraZeneca is recruiting employees for the Krakow office, whose activities will focus mainly on the development of computer systems used during a clinical trial in the area of research process management or collection of clinical data.
Barbara Kozierkiewicz, Director of Global Clinical Systems and Vice President of the Management Board of AstraZeneca Pharma Poland, adds – We are extremely pleased that we will open a new AstraZeneca office in Poland. Krakow is an excellent location for such investments – it is one of the leading academic centers in the country, the business center of southern Poland and the seat of many medical and biotechnology start-ups, as well as those operating in the field of IT, AI and data management.
As part of the development, AstraZeneca envisages further cooperation with Sano – Centre for Computational Personalised Medicine – International Research Foundation – the aim development of new computational methods, algorithms, models and technologies related to personalized medicine.
President Sano, Arkadiusz Sitek expressed his hopes for the development of cooperation, adding: – I believe that together we will manage to do a lot of good for the future of medicine, and above all for patients not only in Poland, but all over the world.
AstraZeneca is a British-Swedish biopharmaceutical company that has been operating on the Polish market for 30 years. Currently, it is known mainly from research aimed at counteracting the development of the COVID-19 pandemic. In our country, it employs approx 2.3 thousand people of which over 1.5 thousand deal with key research and development processes on a global scale. In 2020, the company was given the status of a Research and Development Center.
Source of information: www.astrazeneca.pl
